Search for: "MAJOR PHARMACEUTICALS"
Results 261 - 280
of 4,369
Sort by Relevance
|
Sort by Date
14 Feb 2023, 3:10 am
In the vast majority of cases, patents are later revoked because of state of the art that could and should have been found by the EPO but was not. [read post]
11 Feb 2023, 3:54 am
The issue was discussed earlier this month between the EPO and the Industry Patent Quality Charter, an group representing major international corporations, law firms and patent offices. [read post]
10 Feb 2023, 2:17 am
Instead, the general impression was that there was a certain curiosity about the new system, also by pharmaceutical companies with major patent portfolios, which are primarily afraid of 'wasting the opportunity' if they are unable to influence the formation of the Court's first jurisprudence. [read post]
7 Feb 2023, 12:00 pm
Availability of Discounted Drugs Through Contract Pharmacies The major issue in Sanofi Adventis v. [read post]
7 Feb 2023, 8:00 am
These proceedings are contingent on getting a majority approval from 7 district court judges, known as the Judicial Panel on Multidistrict Litigation. [read post]
5 Feb 2023, 1:30 pm
In our tale, the major battle plays out as a lawsuit over a company’s liability for copyright infringements committed by influencers in connection with their marketing of the company. [read post]
2 Feb 2023, 1:58 pm
The key data being questioned is that of the Initiative for Medicines, Access & Knowledge (I-MAK), an advocacy organization that has become a “principal, go-to source” for data on the number of patents and patent applications covering pharmaceutical innovations. [read post]
2 Feb 2023, 1:58 pm
The key data being questioned is that of the Initiative for Medicines, Access & Knowledge (I-MAK), an advocacy organization that has become a “principal, go-to source” for data on the number of patents and patent applications covering pharmaceutical innovations. [read post]
1 Feb 2023, 9:05 pm
Pfizer was a major contributor to the level of healthcare M&A, announcing a number of deals, including its $11.6 acquisition of Biohaven Pharmaceuticals, $5.4 billion acquisition of Global Blood Therapeutics and $525 million acquisition of ReViral. [read post]
1 Feb 2023, 8:12 am
Renovus Capital Partners has announced it has completed a majority investment in Thomas J Paul (TJP). [read post]
1 Feb 2023, 12:00 am
(Neo attempted to rely on the dissenting opinions in WesternGeco, but unsurprisingly Arnold LJ was more persuaded by the majority.) [read post]
31 Jan 2023, 6:36 pm
Ortho Pharmaceutical Corp., 788 F. 2d 741, 744–745 (11th Cir. 1986). [read post]
31 Jan 2023, 12:53 am
The FCC upheld parts of the complaint, due to procedural flaws: the German Act of Approval of the UPCA should have been ratified by a a two-thirds majority in both chambers of the Bundestag, and this hadn’t been the case. [read post]
30 Jan 2023, 5:09 pm
Tisi has been a nationally recognized trial and appellate lawyer with extensive experience litigating mass tort, pharmaceutical, medical device, and major personal injury cases. [read post]
27 Jan 2023, 4:40 pm
As a result, the vast majority of new cases, hospitalizations and deaths occurred among the unvaccinated. [read post]
26 Jan 2023, 6:35 pm
For example, many cannabis patent holders are pharmaceutical companies and research institutions, instead of criminals. [read post]
25 Jan 2023, 1:48 pm
Renovus Capital Partners has announced it has made a majority investment in ToxStrategies. [read post]
25 Jan 2023, 8:55 am
They had pharmaceutical companies, chemical companies, oil and gas companies, you name it, I have them as my clients. [read post]
23 Jan 2023, 4:15 am
Aug. 5, 2022) -- affirming district court’s decision that Exemption 4 protected portions of pharmaceutical company's successful application for accelerated approval of a drug. [read post]
17 Jan 2023, 4:28 pm
[Register and see the Agenda here] The session has three key substantive areas: The extent and impact of pharmaceutical and biotech companies acting in a two-faced manner: Arguing to the USPTO that their treatments represent major changes from what was previously done (and thus patentable); while simultaneously arguing to the FDA that then later arguing that these same treatments are quite similar to what is already on the market (and thus safe for use). [read post]
